AIDOT (previously Buzzpole)
Leveraging Artificial Intelligence for a Healthier Future

Cancer treatment has been a subject of intense research for many years. In addition to cancer being the number one cause of death worldwide, 30 percent of patients who recover from cancer develop other disorders. This has sent the doctors on the hunt for assistance in deciding early treatment options, much before the cancer is diagnosed. Such early treatment and disorder prediction is exactly where AIDOT excels. AIDOT’s tumor prediction by abnormality detection (in a single click) through artificial intelligence (AI) reduces both morbidity and mortality. A pioneer in next-gen medical diagnostic technology, AIDOT presents its clinical decision support system (CDSS) comprising products such as Cerviray A.I. and NAO Detection A.I to interpret abnormalities well in advance.

Conventionally, AI solutions tend to be used in diagnosis with radiology images like X-ray, CT, and MRIs. AIDOT, however, takes a different approach and has developed its AI solutions for abnormality detection through cervical colposcopy inspection, and risk prediction of brain arterial rupture, and infarction with carotid artery plaque to assist gynecologists and neurosurgeons.

The inception of AIDOT was inspired by the fact that AI’s top priority is medical healthcare. Realizing that the contribution of AI towards healthcare cannot be achieved by human skills alone, Jae-Hoon Jeong, CEO of AIDOT, hired executives with medical/healthcare experience. “We focus on ‘AI for Medical Healthcare’ to assist non-radiologist healthcare personnel (HCP) in reducing their time and fatigue,” states Jeong.

Early detection and risk prediction of cancer is now possible with AIDOT’s solutions, Cerviray A.I. and NAO.

Cerviray A.I. is a remote screening solution for dysplasia without the barrier of morphological knowledge and skills. Generally, when cervical cancer shows symptoms, cancer has already metastasized—emphasizing the need for early detection. Cerviray leverages visual inspection with acetic acid (VIA) for colposcopy to determine any abnormality in the cervix area. As a first step, Cerviray A.I. for Patients is used for patients undergoing screening in hospitals to capture the image of the cervical area, upload it, and generate the report. Next, the diagnosis is done using AI deep learning and the result—the possibility of getting cancer—is displayed. Cerviray A.I. for Experts is used to create a report based on the AI diagnosis, where the doctor gives the final diagnosis. Cerviray A.I. for HQ is a web-based management system, which has features like report management to deliver diagnosis report within a day. The Digital Colposcope is a compact and portable device with exceptional performance for accurate, easy, and swift screening. Overall, the Cerviray solution enables practitioners unfamiliar with detecting cervical dysplasia lesion to easily and quickly detect it with reduced false negatives.

In January 2019, AIDOT deployed Cerviray in one of the large Chinese clinics. Post implementation, the clinic benefitted with a reduction in the time of cytology dependent tests from 30 days to less than an hour and an increase in the number of early detection cases of cervical cancer over ten times their original detection rate.

"We focus on ‘AI for Medical Healthcare’ to assist non-radiologist healthcare personnel (HCP) in reducing their time and fatigue"

Moreover, AIDOT’s NAO Detection A.I is an aneurysm bleeding predictive screening system. About 15 percent of patients suffering from brain aneurysm rupture die as doctors are unable to decide between embolization or surgery at the right time. NAO Detection assists doctors by not only predicting brain bleeding but also predicting challenging emergency treatment and managing early diagnosis. Based on AI learning engine, NAO Detection can detect brain hemorrhage and send emergency readings to doctors through its mobile system.

Making the future healthier through technology, AIDOT aims to build its competency with an exclusive focus on medical practitioners and reducing the inaccuracies of medical technology. “With our solutions, our partners will be able to lead the healthcare domain by introducing the novel CDSS system and realize every practitioner’s wish for standardization of diagnostic processes,” concludes Jeong.